公开(公告)号：US20170198038A1

公开(公告)日：2017-07-13

申请号：US15321650

申请日：2015-06-23

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Nadia ANCERIZ ,  Ariane MOREL ,  Benjamin ROSSI

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K16/2866 ,  C07K2317/31 ,  C07K2317/71 ,  C07K2317/92 ,  C07K2319/30

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20220135676A1

公开(公告)日：2022-05-05

申请号：US17530510

申请日：2021-11-19

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Benjamin ROSSI

IPC: C07K16/28 ,  C07K16/00 ,  C07K16/30

Abstract: Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20240141042A1

公开(公告)日：2024-05-02

申请号：US18490804

申请日：2023-10-20

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Nadia ANCERIZ ,  Ariane MOREL ,  Benjamin ROSSI

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  C07K16/2866 ,  C07K2317/31 ,  C07K2317/71 ,  C07K2317/92 ,  C07K2319/30

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infections disease.

公开(公告)号：US20220213202A1

公开(公告)日：2022-07-07

申请号：US17566142

申请日：2021-12-30

Applicant: INNATE PHARMA ,  SANOFI

Inventor： Céline AMARA ,  Céline NICOLAZZI ,  Marielle CHIRON ,  Francis DUFFIEUX ,  Jochen BENINGA ,  Angela VIRONE-ODDOS ,  Laurent GAUTHIER ,  Ariane THIELENS ,  Benjamin ROSSI

IPC: C07K16/28 ,  A61P35/02

Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-γ receptor.
The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).

公开(公告)号：US20230099801A1

公开(公告)日：2023-03-30

申请号：US17876164

申请日：2022-07-28

Applicant: INNATE PHARMA

Inventor： Stéphanie CHANTEUX ,  Nicolas GOURDIN ,  Carine PATUREL ,  Ivan PERROT ,  Benjamin ROSSI

IPC: C07K16/40 ,  C07K16/28 ,  A61K39/00 ,  C12N9/14 ,  A61P35/00 ,  A61K9/00 ,  G01N33/574

Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.

公开(公告)号：US20200048345A1

公开(公告)日：2020-02-13

申请号：US15738506

申请日：2016-06-23

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Benjamin ROSSI

IPC: C07K16/28

Abstract: Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20190218304A1

公开(公告)日：2019-07-18

申请号：US16370789

申请日：2019-03-29

Applicant: INNATE PHARMA

Inventor： Stéphanie CHANTEUX ,  Nicolas GOURDIN ,  Carine PATUREL ,  Ivan PERROT ,  Benjamin ROSSI

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/40 ,  A61K39/395 ,  A61K31/282

CPC classification number: C07K16/2896 ,  A61K31/282 ,  A61K39/3955 ,  A61K39/39558 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/40 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 in the treatment of cancer to potentiate the activity of an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells.

公开(公告)号：US20190048093A1

公开(公告)日：2019-02-14

申请号：US16173114

申请日：2018-10-29

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Nadia ANCERIZ ,  Ariane MOREL ,  Benjamin ROSSI

IPC: C07K16/28

Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

公开(公告)号：US20170210802A1

公开(公告)日：2017-07-27

申请号：US15321674

申请日：2015-06-23

Applicant: INNATE PHARMA

Inventor： Laurent GAUTHIER ,  Benjamin ROSSI

IPC: C07K16/28 ,  C07K16/30

CPC classification number: C07K16/2803 ,  C07K16/00 ,  C07K16/2809 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.